inactivated poliovirus vaccine (IPV)
GPTKB entity
Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:age_group |
2 months
|
| gptkbp:availability |
widely available
|
| gptkbp:average_temperature |
2-8 ° C
|
| gptkbp:can_be_combined_with |
gptkb:oral_poliovirus_vaccine_(OPV)
|
| gptkbp:clinical_trial |
extensively tested
|
| gptkbp:contraindication |
severe allergic reaction to vaccine components
|
| gptkbp:defense |
recommended for all children
|
| gptkbp:developed_by |
gptkb:Jonas_Salk
|
| gptkbp:dosage_form |
4-6 years
|
| gptkbp:dose_schedule |
3 doses
|
| gptkbp:first_introduced |
gptkb:1955
|
| https://www.w3.org/2000/01/rdf-schema#label |
inactivated poliovirus vaccine (IPV)
|
| gptkbp:is_effective_against |
95% or higher
|
| gptkbp:is_recommended_by |
gptkb:Centers_for_Disease_Control_and_Prevention_(CDC)
gptkb:World_Health_Organization_(WHO) |
| gptkbp:is_vulnerable_to |
vaccine hesitancy
collaboration with NGOs long-lasting immunity approved by FDA ongoing research for improvements educational programs for parents administered by healthcare professionals subunit vaccine increased public awareness campaigns liquid suspension high in developed countries significantly reduced polio cases monitored for safety and efficacy 4 doses recommended in some countries cost-effective in preventing polio distributed through public health systems important for global health initiatives induces strong immune response part of global vaccination campaigns updated regularly based on research |
| gptkbp:not_live_virus |
contains inactivated virus
|
| gptkbp:part_of |
routine immunization schedule
|
| gptkbp:produced_by |
various pharmaceutical companies
|
| gptkbp:route_of_administration |
intramuscular injection
|
| gptkbp:safety |
generally safe
|
| gptkbp:serotype_coverage |
all three serotypes
|
| gptkbp:side_effect |
injection site reactions
mild fever |
| gptkbp:suitable_for |
immunocompromised individuals
|
| gptkbp:targets |
gptkb:poliomyelitis
|
| gptkbp:type |
inactivated vaccine
|
| gptkbp:used_in |
polio eradication efforts
|
| gptkbp:vaccine_impact_on_health |
improves public health outcomes
|
| gptkbp:vaccine_outreach |
community outreach programs
|
| gptkbp:vaccine_regulation |
regulated by health authorities
|
| gptkbp:vaccine_success |
contributed to polio eradication in many regions
|
| gptkbp:vaccine_variants |
new formulations under development
|
| gptkbp:bfsParent |
gptkb:poliomyelitis
|
| gptkbp:bfsLayer |
5
|